Loading ...
EXAMINE(passive) was designedA global , large , randomized , double - blind , placebo - controlled clinical trial
usual care ) control(passive) is designedThis randomized , double - blind , placebo - controlled clinical trial with a wait list
These beneficial effectsledto a multi - center , randomized , placebo - controlled trial
informationwill leadto larger placebo - controlled double - masked randomized clinical trials
to enroll at least 32 adult patients with CF who have two Class(passive) was designedThe randomized , double - blind , placebo - controlled Phase 1/2 clinical trial of MRT5005
to enroll at least 32 adult patients with CF who have two Class(passive) is designedThe randomized , double - blind , placebo - controlled Phase 1/2 clinical trial of MRT5005
to assess the safety , tolerability , and pharmacokinetics of oral IW-6463 in healthy volunteers(passive) is designedThe randomized , placebo - controlled Phase 1 clinical study
Adverse ReactionsResultingin Discontinuation of TreatmentIn placebo - controlled clinical trials
to evaluate the effect of rh - lactoferrin in PLWHIV who were aged 40 years or older(passive) was designedThis randomized , placebo - controlled , cross - over clinical trial ( NCT01830595
As a result of being a Principal Investigator in my first clinical trial ( with support of my Mentors ) , I learned ... , and Ito designhow ... implement a double - blind and placebo - controlled randomized clinical trial
As a result of being a Principal Investigator in my first clinical trial ( with support of my Mentors ) , I learned ... , and Ito designimplement a double - blind and placebo - controlled randomized clinical trial
As a result of being a Principal Investigator in my first clinical trial ( with support of my Mentors ) , I learnedto designand implement a double - blind and placebo - controlled randomized clinical trial
conducted over a total period of four weeks(passive) was designedA randomized , double - blinded , placebo controlled clinical trial
well conducted(passive) was ... designeda prospective , randomized , double - blind , placebo - controlled clinical trial
dendritic cell - vaccine - based immunotherapy for brain tumorshas ledto multi - institutional , randomized placebo - controlled clinical trials
researchersdesigneda randomized , double - blind , placebo - controlled clinical trial
The researchersdesigneda randomized , double - blind , placebo - controlled clinical trial
This studydesignedas a double - blind randomized placebo - controlled clinical trial
Based on the findings of this initial trial , OXIS is planningto designand put into place a placebo - controlled randomized clinical trial of ErgoFlex
Investigatorsdesigneda randomized , double - blind , placebo - controlled clinical trial
to assess the safety , tolerability and plasma concentrations of single ascending doses of WVE-210201 administered intravenously in DMD patients with gene mutations amenable to exon 51 skipping(passive) is designedThe multicenter , double - blind , placebo - controlled clinical trial
well(passive) was really ... designeda randomized , double - blind , placebo - controlled clinical trial
Depression312<1Adverse ReactionsResultingin Discontinuation of TreatmentIn placebo - controlled clinical trials
The scientistsdesigneda randomized , placebo - controlled clinical trial
QJ , JJ , XT , and PLdesignedthe randomized placebo - controlled trial
Dr. Jessica Peatross ... driveleadthe randomized and placebo - controlled MyDx clinical trials
a SPR720 Phase 1 clinical trialdesignedas a double - blind , placebo - controlled clinical trial
C. Kent Kwoh , M.D. , that showed participants " with mild to moderate osteoarthritis who drank 1,500 mg glucosamine hydrochloride dissolved in lemonade each day for 6 months(passive) led bya randomized , placebo - controlled trial
Infectiongenerally resultsfrom a placebo - controlled clinical trial
Clinical Trial ; Multicenter Study(passive) was designedClinical Trial ; Multicenter Study
to assess the efficacy , safety and tolerability of tecemotidedesignedto assess the efficacy , safety and tolerability of tecemotide
to evaluate the safety , tolerability and efficacy of tirasemtiv in patients with ALSdesignedto evaluate the safety , tolerability and efficacy of tirasemtiv in patients with ALS
to evaluate the safety anddesignedto evaluate the safety and
The study(passive) was designedThe study
to assess the efficacy , safety and tolerability of tecemotidedesignedto assess the efficacy , safety and tolerability of tecemotide
to evaluate the efficacy and safety of adjunctive use of oral AV-101 for MDD in patients with an inadequate response to standard antidepressant therapy with either an FDA - approved selective serotonindesignedto evaluate the efficacy and safety of adjunctive use of oral AV-101 for MDD in patients with an inadequate response to standard antidepressant therapy with either an FDA - approved selective serotonin
to assess the efficacy , safety and tolerability of tecemotide in patients suffering fromdesignedto assess the efficacy , safety and tolerability of tecemotide in patients suffering from
This study(passive) is designedThis study
to assess the efficacy , safetydesignedto assess the efficacy , safety
to test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with typedesignedto test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with type
to test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults withdesignedto test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with
to enroll 300 patientsdesignedto enroll 300 patients
This study(passive) was designedThis study
the study(passive) was designedthe study
to evaluate the safety , tolerability and potential efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis ( ALSdesignedto evaluate the safety , tolerability and potential efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis ( ALS
as a followdesignedas a follow
Health Study(passive) was designedHealth Study
to evaluate the feasibility , safety , and effect of Combo , MSCs alone , and CSCs alone compared with placebo as well as each other in subjects with heart failure of ischemic etiologydesignedto evaluate the feasibility , safety , and effect of Combo , MSCs alone , and CSCs alone compared with placebo as well as each other in subjects with heart failure of ischemic etiology
to test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with type III SMA.designedto test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with type III SMA.
to test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with type III SMAdesignedto test the efficacy and safety of the combined treatment of valproic acid in ambulatory adults with type III SMA
to assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells and c - kit+ cardiac stem cells both alone and in combinationdesignedto assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells and c - kit+ cardiac stem cells both alone and in combination
to enroll 300 patients in North Americadesignedto enroll 300 patients in North America
to evaluate vitamins C ( 500 mg ) , E ( 400 IU ) , and beta - carotene ( 15 mg ) , with or without zinc ( zinc oxide 80 mgdesignedto evaluate vitamins C ( 500 mg ) , E ( 400 IU ) , and beta - carotene ( 15 mg ) , with or without zinc ( zinc oxide 80 mg
to assess the safety and efficacy of Makena ( hydroxyprogesterone caproate injection , 250 mg / mLdesignedto assess the safety and efficacy of Makena ( hydroxyprogesterone caproate injection , 250 mg / mL
to evaluate whether zidovudine ( AZT ) administered to HIV - infected pregnant women and their infantsdesignedto evaluate whether zidovudine ( AZT ) administered to HIV - infected pregnant women and their infants
to assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cells both alone and in combination ( Combodesignedto assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cells both alone and in combination ( Combo
to enroll 300 patients in North America and Europe who have suffered moderate to moderate - severe ischemic strokedesignedto enroll 300 patients in North America and Europe who have suffered moderate to moderate - severe ischemic stroke
to assess the safety and effectiveness of a daily oral dose of Truvada for HIV prevention among women in sub - Saharan Africadesignedto assess the safety and effectiveness of a daily oral dose of Truvada for HIV prevention among women in sub - Saharan Africa
to assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cardiac stem cells ( CSCs ) both alone and in combination ( Combo ) , compared to placebo ( cell - free Plasmalyte - A medium ) as well as each other , administered by transendocardial injection in subjects with ischemic cardiomyopathydesignedto assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cardiac stem cells ( CSCs ) both alone and in combination ( Combo ) , compared to placebo ( cell - free Plasmalyte - A medium ) as well as each other , administered by transendocardial injection in subjects with ischemic cardiomyopathy
This Phase III(passive) is designedThis Phase III
to assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cardiac stem cells ( CSCs ) both alone and in combination ( Combodesignedto assess feasibility , safety , and effect of autologous bone marrow - derived mesenchymal stem cells ( MSCs ) and c - kit+ cardiac stem cells ( CSCs ) both alone and in combination ( Combo
to evaluate the safety and efficacy of LMSCs ( Longeveron Mesenchymal Stem Cells ) or placebo in subjects with Alzheimer 's Diseasedesignedto evaluate the safety and efficacy of LMSCs ( Longeveron Mesenchymal Stem Cells ) or placebo in subjects with Alzheimer 's Disease
to evaluate the efficacy of statin treatment in reducing major cardiovascular events and deathdesignedto evaluate the efficacy of statin treatment in reducing major cardiovascular events and death
to evaluate the feasibility , safety , and effect of Combo , MSCs alone , and CSCs alonedesignedto evaluate the feasibility , safety , and effect of Combo , MSCs alone , and CSCs alone
to assess the efficacy and safety of Chantix for smoking cessation in 700 patients aged 35 to 75 years with stable , documented cardiovascular disease ( other than , ordesignedto assess the efficacy and safety of Chantix for smoking cessation in 700 patients aged 35 to 75 years with stable , documented cardiovascular disease ( other than , or
to evaluate whetherdesignedto evaluate whether
to assess the efficacy and safety of Chantix for smoking cessation in 700 patients aged 35 to 75 years with stable , documented cardiovascular disease ( other than , or in addition to , hypertensiondesignedto assess the efficacy and safety of Chantix for smoking cessation in 700 patients aged 35 to 75 years with stable , documented cardiovascular disease ( other than , or in addition to , hypertension
to enroll 300 patients primarily in North America and Europe who have suffered moderate to moderate - severe ischemic strokedesignedto enroll 300 patients primarily in North America and Europe who have suffered moderate to moderate - severe ischemic stroke
Our Phase 2 multi - center(passive) was designedOur Phase 2 multi - center